MilliporeSigma

The speed at which we can test a medicine’s safety and efficacy directly affects the progress of drug development. Hear from Melisa Wilson as she shares the story behind our new Blazar CHO Animal Origin Free panel and how it’s accelerating the delivery of life-changing medicines to patients with greater speed and safety.

Parkinson’s is one of the fastest-growing neurological disorders, affecting 10 million people today. Our collaboration with The Michael J. Fox Foundation for Parkinson's Research brings SMC immunoassay technology to the scientific community. This technology detects biomarker changes, enabling researchers to measure how different therapies impact disease progression and improve treatment approaches.

Our Molsheim, France site has gone PINK in October! Once again, our campus in Molsheim has been lit up in pink to bring awareness to breast cancer. Local employees also participate in fundraising events to support the fight against breast cancer. #BreastCancerAwareness

With over 300,000 products in our portfolio, we’ve learned a lot about scaling up a product from pilot batches to commercial manufacturing. Now, we leverage this expertise in our Contract Manufacturing Services to help customers scale their products for market. Learn more: http://ms.spr.ly/6044mfO96

In September and October, we proudly celebrated the rich heritage of our Latino/Hispanic colleagues. Our Employee Resource Group, HOLA, is leading the way across Merck KGaA, Darmstadt, Germany with initiatives to honor #HispanicHeritageMonth in the U.S. and beyond. Sebastián Arana A., Alessandra Richardson, PhD, CMPP, Andrea Valencia, Global EMBA EMD Serono EMD Electronics

Hear from experts Melisa Wilson and Alexandra Fajardo as they explain biosafety testing, why it's essential in drug production, and how the opening of our new Rockville biosafety testing site will help foster even faster innovations.

Join us on LinkedIn for a live and interactive panel discussion to explore the future of ADCs in cancer treatment. The discussion will focus on recent advancements in technology and integration with other therapies. Key topics will include innovations in antibody engineering, linker chemistry, payload selection, the role of biomarkers, and challenges in manufacturing. This event is an excellent opportunity for experts, researchers, clinicians, and industry professionals to gain insights into the latest developments and future directions of ADCs. Click Attend to RSVP.

Test yourself! One challenge drug makers face is the poor solubility of active pharmaceutical ingredients (APIs). When taken by a patient, the API within the drug product should be soluble, meaning it should absorb into the body. And yet, 70% of drugs in development are poorly soluble. Knowing this, which of the below techniques do drug makers use to combine API with one or more compounds to overcome solubility challenges? Hint: Find out how our AI-based mPredict service can expedite your drug development process and help you overcome solubility issues. http://ms.spr.ly/6043mNhpS?

Join us next week for an interactive discussion on the future of ADCs in cancer treatment! Our panel of experts will cover advancements in antibody engineering, linker chemistry, biomarkers, and more. Register for the free event here: http://ms.spr.ly/6048mIL6y

BIG news! We just opened our new €290 million biosafety testing facility in Rockville, USA. Our largest biosafety testing investment ever, the new space will help ensure the medicines we take are safe and effective. This new hub brings our testing teams in Rockville together into a single facility, fostering even more innovation, faster. The space enables advances in automation and digitalization and features novel solutions like the Blazar CHO Animal Origin Free panel, cutting viral test timelines by 60%. Read how we are ensuring the safety of the world's medicines for patients here: http://ms.spr.ly/6041mx9kX